An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time

BJU International

Volumn 110, Issue 3, 2012, Pages 375-381

  Inman, Brant A ^a   Zhang, Jingyu ^b   Shah, Nilay D ^c   Denton, Brian T ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c Mayo Clinic   (United States)

^d North Carolina State University   (United States)

Author keywords

prostate cancer; prostate specific antigen; PSA doubling time; PSA percentage change; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SCREENING; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GROUPS BY AGE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; PROSTATE SPECIFIC ANTIGEN PERCENTAGE CHANGE; PROSTATE SPECIFIC ANTIGEN VELOCITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84863725759     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10925.x     Document Type: Article

References (33)

1. Etzioni R, Gulati R, Falcon S, Penson DF,. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008; 28: 323-31 (Pubitemid 351713299)
2. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF,. Cancer surveillance series: interpreting trends in prostate cancer-part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1033-9 (Pubitemid 29293042)
3. Feuer EJ, Merrill RM, Hankey BF,. Cancer surveillance series: interpreting trends in prostate cancer-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1025-32 (Pubitemid 29293041)
4. Hankey BF, Feuer EJ, Clegg LX, et al,. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-24 (Pubitemid 29293040)
5. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-9
6. Daskivich TJ, Regan MM, Oh WK,. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006; 176: 1927-37 (Pubitemid 44633182)
7. Yu X, Han M, Loeb S, et al,. Comparison of methods for calculating prostate specific antigen velocity. J Urol 2006; 176: 2427-31; discussion 2431 (Pubitemid 44755070)
8. Ulmert D, Serio AM, O'Brien MF, et al,. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26: 835-41 (Pubitemid 351398073)
9. Benecchi L, Pieri AM, Destro Pastizzaro C, Potenzoni M,. Optimal measure of PSA kinetics to identify prostate cancer. Urology 2008; 71: 390-4 (Pubitemid 351374708)
10. Melton LJ III,. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 266-74
11. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72; discussion 207-12 (Pubitemid 351193639)
12. Zhou XH,. Correcting for verification bias in studies of a diagnostic test's accuracy. Stat Methods Med Res 1998; 7: 337-53
13. Begg CB, Greenes RA,. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 1983; 39: 207-15
14. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM,. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-42 (Pubitemid 36886239)
15. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC,. PredictABEL: an R package for the assessment of risk prediction models. Eur J Epidemiol 2011; 26: 261-4
16. Vickers A, Savage C, O'Brien M, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
17. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection. V.2.2010. Available at:. Accessed 7 May 2010
18. Prostate-Specific Antigen best practice statement: 2009 update. 2009. Available at:. Accessed 7 May 2010
19. EAU guidelines on prostate cancer. 2010. Available at:. Accessed 7 May 2010
20. Prostate Cancer: Early Detection. 2010. Available at:. Accessed 7 May 2010
21. Connolly D, Black A, Murray L, Nambirajan T, Keane P, Gavin A,. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis. BJU Int 2008; 101: 1507-12 (Pubitemid 351704021)
22. Sölétormos G, Semjonow A, Sibley P, et al,. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51: 1342-51 (Pubitemid 41060864)
23. Connolly D, Black A, Murray L, Napolitano G, Gavin A, Keane P,. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 1044-50
24. Vickers A, Ulmert D, Serio A, et al,. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 2007; 121: 2212-7 (Pubitemid 47585600)
25. Sun L, Moul JW, Hotaling JM, et al,. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int 2007; 99: 753-7 (Pubitemid 46439564)
26. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM,. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99: 1510-5 (Pubitemid 351767238)
27. Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, Metter EJ,. Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology 2011; 77: 143-7
28. Pinsky P, Andriole G, Crawford E, et al,. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer 2007; 109: 1689-95 (Pubitemid 46595706)
29. Schröder F, Roobol M, van der Kwast T, Kranse R, Bangma C,. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006; 49: 460-5; discussion 465 (Pubitemid 43259552)
30. Raaijmakers R, Wildhagen M, Ito K, et al,. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004; 63: 316-20 (Pubitemid 38234427)
31. Vickers AJ, Wolters T, Savage CJ, et al,. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009; 56: 753-60
32. Thompson IM, Ankerst DP, Chi C, et al,. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34 (Pubitemid 43898816)
33. Justice AC, Covinsky KE, Berlin JA,. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-24 (Pubitemid 29135805)